Urinary osteocalcin and other markers of bone metabolism: The effect of risedronate therapy

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 6, 2008, Pages 459-463

  Kumm, Jaanika ^a,d   Ivaska, Kaisa K ^b,c   Rohtla, Kadri ^a   Väänänen, Kalervo ^c   Tamm, Agu ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TURKU   (Finland)

^d NONE   (Estonia)

Author keywords

Antiresorptive therapy; Bone markers; Bone mineral density; Osteoporosis; Postmenopause

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KINETICS; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; THERAPY EFFECT; URINALYSIS; URINE LEVEL;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 52949109136     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701832237     Document Type: Article

References (21)

1. Power MJ, Fottrell PF. Osteocalcin: Diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991;28:287-335.
2. Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Väänänen HK. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 2004;18:18361-9.
3. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-64.
4. Farrugia W, Melick RA. Metabolism of osteocalcin. Calcif Tissue Int 1986;39:234-8.
5. Taylor AK, Linkhart S, Mohan S, Christenson RA, Singer FR, Baylink DJ. Multiple osteocalcin fragments in human urine and serum as detected by a mid-molecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 1990;70:467-72.
6. Baumgrass R, Williamson MK, Price PA. Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B,D, L, H and S. J Bone Miner Res 1997;12:447-55.
7. Srivastava AK, Mohan S, Singer FR, Baylink DJ. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 2002;31:62-9.
8. Ivaska KK, Hellman J, Likojärvi J, et al. Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun 2003;306:973-80.
9. Ivaska KK, Pettersson K, Nenonen A, et al. Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 2005;51:2362-5.
10. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;4:433-9.
11. Hamdy RC, Chesnut CH III, Gass ML, et al. Review of treatment modalities for postmenopausal osteoporosis. South Med J 2005;10:1000-14.
12. Stepan JJ, Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clin Chim Acta 1999;288:121-35.
13. Ivaska KK, Käkönen S, Gerdhem P, Obrant KJ, Petersson K, Väänänen K. Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005;51:618-28.
14. Akesson K, Käkönen SM, Josefsson PO, et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 2005;23:30-5.
15. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
16. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
17. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 1995;80:2447-50.
18. Halleen JM, Ylipahkala H, Alatalo SL, et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral denisty. Calcif Tissue Int 2002;71:20-5.
19. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
20. Ravn P, Clemmesen B. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999;24:237-44.
21. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.